15 December 2016 
EMA/CHMP/813686/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ameluz 
5-aminolevulinic acid 
On 15 December 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Ameluz. The marketing authorisation holder for this medicinal product is Biofrontera Bioscience GmbH. 
The CHMP adopted a new indication as follows: 
“Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due 
to possible treatment-related morbidity and/or poor cosmetic outcome in adults.” 
For information, the full indications for Ameluz will be as follows: 
“Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 
2; see section 5.1) and of field cancerization in adults. 
Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to 
possible treatment-related morbidity and/or poor cosmetic outcome in adults.”  
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
